The IMID Forum

Discussing AxSpA: Upadacitinib in nr-axSpA and certolizumab pegol by baseline MRI and CRP status

Aug 12, 2024
Guest
Professors Hideto Kameda
Guest
Xenofon Baraliakos
Join Professors Hideto Kameda and Xenofon Baraliakos for insights on upadacitinib in nr-axSpA and certolizumab pegol treatment. Topics include results from a phase 3 trial, analysis of upadacitinib treatment, longer-term safety analysis, clinical outcomes of certolizumab pegol, and response rates based on MRI and CRP status in nr-axSpA patients.
Ask episode
Chapters
Transcript
Episode notes
1
Intro
00:00 • 3min
2
Analysis of Upadacitinib treatment for Non-Radiographic Axial Spondyloarthritis
02:34 • 5min
3
Longer-Term Safety Analysis of New Drug Treatment
07:46 • 5min
4
Clinical Outcomes of Certolizumab Pegol in Non-Radiographic Axial Spondyloarthritis
12:49 • 6min
5
Analysis of Response Rates Based on MRI and CRP Status in nr-axSpA Patients
19:18 • 3min